SCHEMBL5065407

SCHEMBL5065407

CC(C)(C)n1cc(N(C(N)=O)c2cc(Oc3nccc(-c4ncco4)n3)ccc2F)cn1

nearest known ligand 0.31

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
RAF1 P04049 1/20 0.31
MAP2K1 Q02750 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3631368 0.77 KDR (0.43) RAF1
SCHEMBL826840 0.77 KDR (0.45)
SCHEMBL5064101 0.67 MAPK14 (0.37) RAF1
SCHEMBL5065440 0.65 KDR (0.42) RAF1
SCHEMBL2447423 0.65 CSF1R (0.40)
SCHEMBL3659669 0.64 KDR (0.43) RAF1
SCHEMBL3660380 0.63 KDR (0.48) RAF1
SCHEMBL3658869 0.63 KDR (0.44) RAF1
SCHEMBL3663211 0.62 KDR (0.42) RAF1
SCHEMBL5068759 0.61 KDR (0.42) RAF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269254-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269254-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES KIT, BRAF, RET RAF1 20/4885MAP2K1 206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.